Claims for Patent: 7,470,522

Summary for Patent: 7,470,522

Title:	Isolated genomic polynucleotide fragments encoding human resistin and the human syntaxin binding protein 2
Abstract:	The invention is directed to isolated genomic polynucleotide fragments that encode human resistin and human syntaxin binding protein 2, vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human resistin and human syntaxin binding protein 2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.
Inventor(s):	Ryan; James W. (Augusta, GA)
Assignee:	Ryogen LLC (Suffern, NY)
Application Number:	11/483,373
Patent Claims:	1. An isolated genomic nucleic acid molecule, said nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule consisting of a nucleic acid sequence which has at least 99% identity to the nucleic acid molecule of SEQ ID NO: 3 and which encodes a polypeptide having the amino acid sequence of SEQ ID NO: 1, wherein said polypeptide inhibits the action of insulin; (b) a fragment of the nucleic acid molecule of (a), said fragment comprising at least nucleotides 19611-20633 of SEQ ID NO: 3 and which encodes a polypeptide having the amino acid sequence of SEQ ID NO: 1, wherein said polypeptide inhibits the action of insulin, and; (c) a nucleic acid molecule that is the full complement of the nucleic acid molecule of (a) or (b). 2. A nucleic acid construct comprising the nucleic acid molecule of claim 1. 3. An expression vector comprising the nucleic acid molecule of claim 1. 4. An isolated recombinant host cell comprising the nucleic acid molecule of claim 1. 5. A method for obtaining a polypeptide which inhibits insulin activity, said method comprising: (a) culturing the recombinant host cell of claim 4 under conditions that provide for the expression of said polypeptide and (b) recovering said expressed polypeptide. 6. A composition comprising the nucleic acid molecule of claim 1 and a carrier. 7. A kit comprising the nucleic acid molecule of claim 1. 8. The kit according to claim 7, in which the nucleic acid molecule is labeled with a detectable substance. 9. A microarray comprising one or more of the nucleic acid molecules of claim 1. 10. A kit comprising the microarray of claim 9. 11. A method of detecting the presence of a nucleic acid sequence of SEQ ID NO: 3, its complementary sequence or fragment thereof in a sample, said method comprising contacting the sample with the nucleic acid molecule of claim 1 and determining whether the nucleic acid molecule binds to said nucleic acid sequence in the sample. 12. A method of identifying a nucleotide sequence variant of the 5'-noncoding region, 3'-noncoding region or intron region of SEQ ID NO: 3 or its complementary sequence comprising: (a) isolating genomic DNA from a subject and (b) determining the presence or absence of a nucleotide sequence variation in said genomic DNA by comparing the nucleotide sequence of SEQ ID NO: 3 with the nucleotide sequence of the isolated genomic DNA and establishing if and where a difference occurs between the two nucleic acid sequences thereby identifying a nucleotide sequence variant of SEQ ID NO: 3, or its complement. 13. The method according to claim 12, wherein said variant encodes a protein that inhibits the action of insulin. 14. An isolated nucleic acid molecule consisting of a non-coding region of the nucleic acid molecule of claim 1, which non-coding region is selected from the group consisting of the 5'-noncoding region shown in sequence segment 20633-38587 of SEQ ID NO:3, the 3'-non coding region shown in sequence segment 1-19610 of SEQ ID NO:3 and the intron region shown in sequence segments 20141-20516 and 19743-20062 of SEQ ID NO:3, or a full complement of said isolated nucleic acid molecule. 15. An isolated nucleic acid molecule consisting of a fragment of the nucleic acid molecule of claim 1, said nucleic acid molecule consisting of a nucleic acid sequence selected from the group consisting of: (a) a sequence of at least 4000 contiguous nucleotides within a region consisting of the sequence of nucleotides from position 20634-38587 of SEQ ID NO:3 and (b) a sequence of a least 600 contiguous nucleotides with the region consisting of the sequence of nucleotides from position 1-19610 of SEQ ID NO:3. 16. An isolated nucleic acid molecule consisting of 20-300 contiguous nucleotides in sequence segments of a non-coding region of the nucleic acid molecule of claim 1, which non-coding region is selected from the group consisting of the 5'-noncoding region shown in sequence segment 20633-38587 of SEQ ID NO:3, the 3'-non coding region shown in sequence segment 1-19610 of SEQ ID NO:3 and the intron region shown in sequence segments 20141-20516 and 19743-20062 of SEQ ID NO:3, or a full complement of said isolated nucleic acid molecule.

Details for Patent 7,470,522

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2025-07-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2025-07-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2025-07-09